You have free access to this content

Cancer

Cover image for Vol. 117 Issue 2

15 January 2011

Volume 117, Issue 2

Pages 231–436

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia : Before or after imatinib? (pages 234–237)

      Ayalew Tefferi

      Article first published online: 26 OCT 2010 | DOI: 10.1002/cncr.25600

      Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      L-asparaginase treatment in acute lymphoblastic leukemia : A focus on Erwinia asparaginase (pages 238–249)

      Rob Pieters, Stephen P. Hunger, Joachim Boos, Carmelo Rizzari, Lewis Silverman, Andre Baruchel, Nicola Goekbuget, Martin Schrappe and Ching-Hon Pui

      Article first published online: 7 SEP 2010 | DOI: 10.1002/cncr.25489

      Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood acute lymphoblastic leukemia (ALL). However, despite the universal inclusion of asparaginase in the combination-chemotherapy protocols, there is much debate on the optimal formulation and dosage of these agents. Selected experts from Europe and the United States have written this article to provide an overview of available evidence to make recommendations for optimal use of asparaginase, especially Erwinase, in the treatment of ALL.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients : A meta-analysis and single-institution experience (pages 250–258)

      Liang-Chih Liu, Julie E. Lang, Ying Lu, Denise Roe, Shelley E. Hwang, Cheryl A. Ewing, Laura J. Esserman, Eugene Morita, Patrick Treseler and Stanley P. Leong

      Article first published online: 3 SEP 2010 | DOI: 10.1002/cncr.25606

      The authors performed both a single-institution study and a meta-analysis to evaluate intraoperative frozen sections (IFS) of sentinel lymph nodes (SLNs) that were obtained during breast cancer surgery. IFS of SLNs was more reliable for detecting macrometastasis than for detecting micrometastasis or isolated tumor cell (Mi/ITC) deposits but it lacked sufficient accuracy to rule out Mi/ITC deposits.

    2. Endocrine Disease
      You have free access to this content
      Clinical and molecular features of papillary thyroid cancer in adolescents and young adults (pages 259–267)

      Menno R. Vriens, Willieford Moses, Julie Weng, Miao Peng, Ann Griffin, Archie Bleyer, Brad H Pollock, Daniel J. Indelicato, Jimmy Hwang and Electron Kebebew

      Article first published online: 7 SEP 2010 | DOI: 10.1002/cncr.25369

      The extent of disease at presentation and survival among adolescents and young adults with papillary thyroid carcinoma differed from that among older patients. The current results indicated that this difference may be caused by candidate genes (extracellular matrix protein 1 [ECM1], v-erb-2 erythroblastic leukemia viral oncogene homolog 2 [ERBB2], urinary plasminogen activator [UPA], 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 [PFKFB2], meis homeobox 2 [MEIS2], and carbonic anhydrase II [CA2]) that are expressed differentially and may play important roles in tumor cell biology.

    3. Gastrointestinal Disease
      You have free access to this content
      First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas (pages 268–275)

      Jonathan R. Strosberg, Robert L. Fine, Junsung Choi, Aejaz Nasir, Domenico Coppola, Dung-Tsa Chen, James Helm and Larry Kvols

      Article first published online: 7 SEP 2010 | DOI: 10.1002/cncr.25425

      The combination of capecitabine and temozolomide is highly active in pancreatic endocrine carcinomas. The side effect profile of this regimen is tolerable.

    4. Genitourinary Disease
      You have free access to this content
      Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer (pages 276–282)

      Ganesh V. Raj, Saumil Karavadia, Bruce Schlomer, Yull Arriaga, Yair Lotan, Arthur Sagalowsky and Eugene Frenkel

      Article first published online: 9 SEP 2010 | DOI: 10.1002/cncr.25429

      Despite level I evidence, neoadjuvant cisplatin-based chemotherapy is given to only 17% of eligible patients with muscle-invasive bladder cancer prior to RC, in a contemporary cohort, even at a high-volume tertiary center. A prospective evaluation is indicated to analyze why more patients do not get neoadjuvant chemotherapy.

    5. You have free access to this content
      Inaccuracies in assignment of clinical stage for localized prostate cancer (pages 283–289)

      Adam C. Reese, Natalia Sadetsky, Peter R. Carroll and Matthew R. Cooperberg

      Article first published online: 22 NOV 2010 | DOI: 10.1002/cncr.25596

      Errors in applying clinical staging criteria for localized prostate cancer are common, but do not explain the inconsistent reliability of clinical stage in predicting prostate cancer outcomes. These findings challenged the utility of a digital rectal examination and/or transrectal ultrasound-based staging system for localized prostate cancer.

    6. You have free access to this content
      The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases (pages 290–300)

      Tamer Abou Youssif, Mona Alam Fahmy, Ismael Herve Koumakpayi, Fernanda Ayala, Saeeda Al Marzooqi, Guangyong Chen, Pheroze Tamboli, Jeremy Squire, Simon Tanguay and Kanishka Sircar

      Article first published online: 9 SEP 2010 | DOI: 10.1002/cncr.25402

      The mammalian target of rapamycin (mTOR) pathway is widely activated in renal cell carcinoma (RCC) metastases across various tumor histologies, nuclear grades, and metastatic sites, suggesting the potential for vertical blockade of multiple steps of this pathway. Patient selection may be improved by mTOR immunostaining of primary RCC.

    7. Gynecologic Oncology
      You have free access to this content
      Molecular typing of epithelial ovarian carcinomas using inflammatory markers (pages 301–309)

      Rouba Ali-Fehmi, Assaad Semaan, Sima Sethi, Haitham Arabi, Sudeshna Bandyopadhyay, Yaser R. Hussein, Michael P. Diamond, Ghasan Saed, Robert T. Morris and Adnan R. Munkarah

      Article first published online: 3 SEP 2010 | DOI: 10.1002/cncr.25588

      In the new proposed classification of ovarian epithelial carcinomas, the more aggressive type II tumors show a higher expression of inflammatory pathway proteins.

    8. You have free access to this content
      Therapeutic role of lymphadenectomy for cervical cancer (pages 310–317)

      Monjri Shah, Sharyn N. Lewin, Israel Deutsch, William M. Burke, Xuming Sun, Thomas J. Herzog and Jason D. Wright

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25408

      Node negative, early stage cervical cancer patients who undergo a more extensive lymphadenectomy have an improved survival.

    9. Head and Neck Disease
      You have free access to this content
      Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer (pages 318–326)

      Johnny Kao, Eric M. Genden, Vishal Gupta, Edelweiss L. Policarpio, Ryan J. Burri, Michael Rivera, Vivek Gurudutt, Peter M. Som, Marita Teng and Stuart H. Packer

      Article first published online: 9 SEP 2010 | DOI: 10.1002/cncr.25374

      In this phase 2 trial, the toxicity and efficacy of concurrent 5-flurouracil, hydroxyurea, cetuximab, and hyperfractionated radiation therapy were studied in patients with advanced (stages III, IVA, and IVB) head and neck cancer. The results indicated that a concurrent schedule of 5-flurouracil, hydroxyurea, and cetuximab plus simultaneous integrated-boost, intensity-modulated radiation is a promising and reasonably well tolerated approach to incorporating molecularly targeted therapy into curative therapy for locally advanced head and neck cancer.

    10. Hematologic Malignancies
      You have free access to this content
      Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia (pages 327–335)

      Aref Al-Kali, Hagop Kantarjian, Jianqin Shan, Roland Bassett, Alfonso Quintás-Cardama, Gautam Borthakur, Elias Jabbour, Srdan Verstovsek, Susan O'Brien and Jorge Cortes

      Article first published online: 15 SEP 2010 | DOI: 10.1002/cncr.25604

      The current event-free survival rate was a more accurate tool that event-free survival for measuring the outcome of patients with chronic myeloid leukemia in chronic phase who frequently are treated and successfully with a subsequent tyrosine kinase inhibitor (TKI) after failure on their first TKI.

    11. You have free access to this content
      Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma (pages 336–342)

      Ruben Niesvizky, Scott Ely, Tomer Mark, Sangeeta Aggarwal, Janice L Gabrilove, John J. Wright, Selina Chen-Kiang and Joseph A Sparano

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25584

      Romidepsin is an histone deacetylase inhibitor that exhibits antiproliferative and apoptotic effects against multiple myeloma cell lines. A phase 2 trial was performed of romidepsin in patients with multiple myeloma who were refractory to standard therapy. Patients with myeloma exhibited evidence of M-protein stabilization and improvement in bone pain and resolution of hypercalcemia. It was concluded that romidepsin, as a single agent, had modest activity but may be used in combination with other agents as adjunctive therapy.

    12. Hepatobiliary Disease
      You have free access to this content
      Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol (pages 343–352)

      Marissa Albert, Matthew V. Kiefer, Weijing Sun, Daniel Haller, Douglas L. Fraker, Catherine M. Tuite, S. William Stavropoulos, Jeffrey I. Mondschein and Michael C. Soulen

      Article first published online: 9 SEP 2010 | DOI: 10.1002/cncr.25387

      In the multidisciplinary management of patients with metastases from colorectal cancer, the addition of chemoembolization to standard surgical and medical therapy provided disease control in 43% and a median survival of 27 months. Liver-directed therapy may offer benefit to select patients with liver-dominant disease.

    13. Lung Disease
      You have free access to this content
      A transcriptional network signature characterizes lung cancer subtypes (pages 353–360)

      Hsun-Hsien Chang, Jonathan M. Dreyfuss and Marco F. Ramoni

      Article first published online: 13 SEP 2010 | DOI: 10.1002/cncr.25592

      A transcriptional network model derived from gene expression microarrays identified a narrow cytoband on chromosome 12 able to characterize lung cancer subtypes. The signature genes were also confirmed by a comparative genomic hybridization analysis.

    14. Peritoneal Disease
      You have free access to this content
      Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma (pages 361–371)

      Sheelu Varghese, Zhaorong Chen, David L. Bartlett, James F. Pingpank, Steven K. Libutti, Seth M. Steinberg, John Wunderlich and H. Richard Alexander Jr.

      Article first published online: 13 SEP 2010 | DOI: 10.1002/cncr.25555

      Malignant peritoneal mesothelioma (MPM) is an understudied cancer. In this study, the authors investigated the molecular nature of MPM to obtain insights into the heterogeneity of its clinical behavior and to identify new therapeutic targets for intervention.

    15. Sarcoma
      You have free access to this content
      Soft tissue sarcoma presenting with metastatic disease : Outcome with primary surgical resection (pages 372–379)

      Peter C. Ferguson, Benjamin M. Deheshi, Peter Chung, Charles N. Catton, Brian O'Sullivan, Abha Gupta, Anthony M. Griffin and Jay S. Wunder

      Article first published online: 9 SEP 2010 | DOI: 10.1002/cncr.25418

      The objective of this study was to assess patient, tumor, and treatment factors that affected overall survival in a group of patients who presented with advanced soft tissue sarcoma (STS) and underwent primary surgery. Patients with STS who presented with pulmonary metastases had an extremely poor prognosis and could undergo primary resection only for local control and palliation of symptoms, whereas patients with STS who presented with isolated lymph node metastases had a much better prognosis, and aggressive surgical resection of the primary tumor and metastases was warranted in an attempt to cure these patients.

    16. You have free access to this content
      Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors (pages 380–389)

      Antti Ylipää, Kelly K. Hunt, Jilong Yang, Alexander J. F. Lazar, Keila E. Torres, Dina C. Lev, Matti Nykter, Raphael E. Pollock, Jonathan Trent and Wei Zhang

      Article first published online: 3 SEP 2010 | DOI: 10.1002/cncr.25594

      By integrating gene copy number data with expression data and clinical information, the authors identified prognostic genes that had recurrent gene copy number alterations and corresponding gene expression changes. The current investigation also revealed 4 subtypes of gastrointestinal stromal tumors with accumulating aberrations in gene copy numbers that were correlated with survival.

    17. Discipline

      Disparities Research
      You have free access to this content
      Policy implications of early onset breast cancer among Mexican-origin women (pages 390–397)

      Patricia Y. Miranda, Anna V. Wilkinson, Carol J. Etzel, Renke Zhou, Lovell A. Jones, Patricia Thompson and Melissa L. Bondy

      Article first published online: 31 AUG 2010 | DOI: 10.1002/cncr.25397

      In this study, half of women with breast cancer cases were diagnosed before age 50 years; in a multivariate model, women who had a family history of breast cancer (odds ratio [OR], 4.3), those who were born in Mexico, those who had high levels of language acculturation (OR, 2.5), and those without health insurance (OR, 1.6) had the highest risk for breast cancer. Because the findings indicated that women of Mexican origin are at high risk for early onset, premenopausal breast cancer, the authors recommended policies that target screening, education, and treatment to prevent increased disparities in mortality.

      Corrected by:

      Erratum: Erratum: Policy Implications of Early Onset Breast Cancer Among Mexican-Origin Women

      Vol. 117, Issue 4, 878, Article first published online: 4 OCT 2010

    18. You have free access to this content
      Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors (pages 398–405)

      Tina W. F. Yen, Linda K. Czypinski, Rodney A. Sparapani, Changbin Guo, Purushottam W. Laud, Liliana E. Pezzin and Ann B. Nattinger

      Article first published online: 7 SEP 2010 | DOI: 10.1002/cncr.25412

      In a cohort of elderly women, 2 socioeconomic factors, a woman's education level and her social support system, were identified as predictors of adjuvant breast cancer hormone therapy use. In these elderly women, those who received hormone therapy and had no insurance coverage for medication costs were significantly less likely to receive an aromatase inhibitor.

    19. Medical Oncology
      You have free access to this content
      Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation (pages 406–413)

      Paul L. Nguyen, Ming H. Chen, Samuel Z. Goldhaber, Neil E. Martin, Clair J. Beard, Daniel E. Dosoretz, Michael J. Katin, Rudi Ross, Sharon A. Salenius and Anthony V D'Amico

      Article first published online: 31 AUG 2010 | DOI: 10.1002/cncr.25597

      In men with a history of coronary artery disease-induced congestive heart failure or myocardial infarction, neoadjuvant hormonal therapy is associated with an excess risk of mortality, which appears to be reduced but not eliminated by prior revascularization. Hormonal therapy must be used cautiously in such men, even if they have been revascularized.

    20. Radiation Oncology
      You have free access to this content
      Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: Is there a difference in outcome between morning and afternoon treatment? (pages 414–420)

      Douglas A. Rahn III, Dibyendu K. Ray, David J. Schlesinger, Ladislau Steiner, Jason P. Sheehan, John M. O'Quigley and Tyvin Rich

      Article first published online: 9 SEP 2010 | DOI: 10.1002/cncr.25423

      Gamma knife radiosurgery for metastatic nonsmall cell lung cancer had better local control, better survival, and a lower rate of central nervous system (CNS)-related cause of death when given early in the day versus late in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.

    21. Translational Research
      You have free access to this content
      Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma (pages 421–434)

      Katie M. Nemeth, Sara Federico, Angel M. Carcaboso, Ying Shen, Paula Schaiquevich, Jiakun Zhang, Merrill Egorin, Clinton Stewart and Michael A. Dyer

      Article first published online: 3 SEP 2010 | DOI: 10.1002/cncr.25574

      The authors report on a comprehensive preclinical trial that used topotecan and carboplatin to treat retinoblastoma. The data reported include pharmacokinetics, tumor response, and toxicity studies to assess the drugs' effectiveness. For the first time, the authors report curing retinoblastoma in mice and preserving vision in long-term survivors.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION